The business of healthcare is rapidly
changing. Physicians are facing significantly lower reimbursement rates for
services provided and the drugs they use in their practice. Now, more than
ever, it is critical for practices to control costs in order to maintain
viability and continue to provide quality care to patients.
Additionally, there are almost 400 new specialty
pharmaceuticals in development with over 100 in late stage development, and it
is estimated that over 60% of these products will likely be administered in a
physician office. The majority of these products in development are for
oncology and rheumatology.